EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment

Benzinga_recent_news01-14

The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg. The company on Wednesday said...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603616558?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-14 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603616558","market":"hk","top_or_hot":-1,"title":"EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment","media":"Benzinga_recent_news","content":"<div>\n<p>The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg.\nThe company on Wednesday said...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg.\nThe company on Wednesday said...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","article_id":"2603616558","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603616558","pubTimestamp":1768395060,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","SCNX":"Scienture Holdings, Inc."},"translate_title":"独家：Penny Stock Scienture的合作伙伴获得用于紧急阿片类药物过量治疗的最高剂量纳洛酮喷雾剂的美国专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCNX":1},"content_text":"The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg.\nThe company on Wednesday said the patent is effective January 6, 2026, with an expiry date of February 5, 2041.\nThe patent was issued to Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P.\nIn March 2025, Scienture LLC, a wholly owned subsidiary of Scienture Holdings Inc. (NASDAQ:SCNX), inked a commercialization pact with Summit for the exclusive U.S. rights to Rezenopy.\nUnder the terms of the collaboration, Summit will manufacture and commercially supply Rezenopy.\nPending certain commercial obligations, Scienture will own the new drug application (NDA) for Rezenopy in its name and be responsible for the sales, marketing, and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.\nThe U.S. Food and Drug Administration (FDA) approved Rezenopy in April 2024. Rezenopy is the highest dosage of naloxone HCl nasal spray approved by the FDA.\nRezenopy (naloxone HCl) Nasal Spray 10mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients.\nIt is intended for immediate administration as emergency therapy in settings where opioids may be present.\nRezenopy nasal spray is for intranasal use only and is supplied as a carton containing two blister packages, each with a single spray device.\nThe newly issued patent is eligible for listing in the FDA's Orange Book and, if listed, may provide additional intellectual property protection supporting the product's U.S. commercialization.\nThe product leverages the proven naloxone hydrochloride molecule and familiar nasal spray form factor, while delivering increased effectiveness against potent opioids.\nAccording to IQVIA data, total annual U.S. naloxone sales reached approximately $154 million, with unit volume of 9.3 million units, underscoring the significant and growing market opportunity.\nScienture reported that third quarter net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand.\nIn November 2025, Scienture announced that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans.\nArbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms.\nSCNX Price Action: Scienture Holdings shares were up 0.13% at $0.54 during premarket trading on Wednesday. The stock is trading near its 52-week low of $0.46, according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603616558","isCrawlerRequest":true}